Sector News

Should Teva buy Mylan? ‘Close call,’ analyst says

March 16, 2015
Life sciences
Rumors have been floating around for months that pickup-hungry Teva may be looking to buy generics competitor Mylan. Some analysts have dismissed the idea, pointing to reasons a buyout wouldn’t work. But with the deal talk persisting, at least one analyst says the underlying logic for a tie-up is sound–as long as it doesn’t happen right away.
 
As Bernstein’s Ronny Gal put it in a note to investors Wednesday, “combining the two companies is reasonable.” First off, there’s potential for substantial cost synergies in manufacturing and R&D–about $1.2 billion, he figures. Teva in particular has been working to cut down on manufacturing costs, and Mylan’s base in India “would certainly help that,” he noted.
 
Teva has also been hyping a return to its generic roots. Last quarter, the Israeli pharma’s generics revenue fell 8% to $2.47 billion, propelling a 4.8% overall sales drop. Total generics sales took a dip during full-year 2014, too. But adding Mylan, another top-5 copycat drugmaker, would give that business a boost.
 
A few factors could still make things complicated in the here-and-now, however. As Gal points out, Teva, which has said it could produce a knockoff of Mylan’s Epipen by late this year, would need to divest its ANDA file if an acquisition takes place. Mylan is also in the middle of its own deal for a large chunk of Abbott’s ($ABT) Netherlands-based generics portfolio, which could make valuing it difficult.
 
Beyond that, Mylan’s execs have tied their compensation to $6.00 in EPS and a share price of $72, meaning the board isn’t likely to accept less than $70 per share, Gal argues. And when he runs the math at that price, a deal looks like it would be 10% to 15% accretive for Teva after it’s completed.
 
“Is this good enough to take on a material deal which will limit flexibility to do other things?” he wrote. “Close call.”
 
Meanwhile, though, Mylan could have other suitors sizing it up. Some have listed on-the-prowl Pfizer ($PFE) as a potential buyer, though Bernstein’s Tim Anderson, for one, wrote in December that tax-advantaged Mylan would be too small to help pharma giant do its own inversion deal.
 
By Carly Helfand
 

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.